Trial document




drksid header

  DRKS00021145

Trial Description

start of 1:1-Block title

Title

Lean European Open Survey on
SARS-CoV-2 (COVID-19)

end of 1:1-Block title
start of 1:1-Block acronym

Trial Acronym

LEOSS

end of 1:1-Block acronym
start of 1:1-Block url

URL of the Trial

https://leoss.net/

end of 1:1-Block url
start of 1:1-Block public summary

Brief Summary in Lay Language

The current Severe Acute Respiratory Syndrome Coronavirus II (SARS-CoV-2) pandemic is a major challenge for medical professionals worldwide, with a daily increase of new infections. There is an urgent need to record confirmed SARS-CoV-2 cases uniformly in order to establish an evidence base for best practice in clinical management of patients with SARS-CoV-2 infection.
We initiated the Lean European Open Survey on SARS-CoV-2 (LEOSS) project, a prospective European multi-center cohort study, to get more in-depth knowledge about the epidemiology and clinical course of patients infected with SARS-CoV-2. Our goal is to establish a quick and simple register that allows anonymous documentation of patients, with the objective to identify independent predictors of outcome in patients with diagnosed infection by SARS-CoV-2. The data will be available for collaborating scientists and results will be publicly available on a regular bases on the project website https://leoss.net/.

end of 1:1-Block public summary
start of 1:1-Block scientific synopsis

Brief Summary in Scientific Language

The current Severe Acute Respiratory Syndrome Coronavirus II (SARS-CoV-2) pandemic is a major challenge for medical professionals worldwide, with a daily increase of new infections. A uniform recording of confirmed SARS-CoV-2 cases can provide information on successful treatment and prevention of severe disease progression. Our project Lean European Open Survey on SARS-CoV-2 (LEOSS) creates an infrastructure for an European-wide documentation of patients with a SARS-CoV-2 infection. The project develops a simple, quick and anonymous documentation. The overall goal is to identify independent predictors of outcome in patients with diagnosed infection by SARS-CoV-2. The data will be available for collaborating scientists and results will be publicly available on a regular bases on the project website https://leoss.net/.

end of 1:1-Block scientific synopsis
start of 1:1-Block forwarded Data

Do you plan to share individual participant data with other researchers?

Yes

end of 1:1-Block forwarded Data
start of 1:1-Block forwarded Data Content

Description IPD sharing plan:

We will present descriptive statistics on the included cases, socio-demographic characteristics and clinical course daily/weekly on our website https://leoss.net/. Furthermore, results of the calculated correlations with treatment strategies, laboratory values and the severity of disease progression and event-time analyses will be presented.

The study protocol and a description of the eCRF will be provided.

An anonymised data set is made available to the cooperation partners in a password-protected manner. A selected part of the entire anonymised data set (e.g. statistics on cases in regions/hospitals of the cooperating centres) will be available to all cooperating centres. Access to the data is regulated by a data use and access policy.

Since the anonymous data set will be passed on to the research community, it will not be possible to keep control over the analyses carried out by international researchers. We will inform via our website that secondary analyses must justify IRB approval based on local laws and regulations.

end of 1:1-Block forwarded Data Content
start of 1:1-Block organizational data

Organizational Data

  •   DRKS00021145
  •   2020/04/08
  •   [---]*
  •   yes
  •   Approved
  •   20-600, Ethikkommission des Fachbereichs Humanmedizin der Johann-Wolfgang-Goethe-Universität Frankfurt am Main
end of 1:1-Block organizational data
start of 1:n-Block secondary IDs

Secondary IDs

  • [---]*
end of 1:n-Block secondary IDs
start of 1:N-Block indications

Health Condition or Problem studied

  •   U07.1 -  Emergency use of U07.1
end of 1:N-Block indications
start of 1:N-Block interventions

Interventions/Observational Groups

  •   Patients with confirmed SARS-CoV-2 infection by PCR diagnosis from nasopharynx, oropharynx, stool, or blood. Rapid tests are an acceptable alternative.
    Within the framework of LEOSS, data on the therapy and the course of treatment of patients infected with SARS-CoV-2 will be documented. The resulting registry will enable the analysis of important questions regarding SARS-CoV-2. Within the scope of the project, no study conditional interventions will be carried out.
end of 1:N-Block interventions
start of 1:1-Block design

Characteristics

  •   Non-interventional
  •   Observational study
  •   Single arm study
  •   Open (masking not used)
  •   [---]*
  •   Uncontrolled/Single arm
  •   Other
  •   Single (group)
  •   N/A
  •   N/A
end of 1:1-Block design
start of 1:1-Block primary endpoint

Primary Outcome

To identify independent predictors of outcome in patients with diagnosed infection by SARS-CoV-2.

end of 1:1-Block primary endpoint
start of 1:1-Block secondary endpoint

Secondary Outcome

1) To assess the incidence of complicated and critical infection by SARS-CoV-2
2) To assess potential risk factors of complicated and critical infection by SARS-CoV-2
3) To assess clinical and sociodemographic characteristics of patients with SARS-CoV-2 infection (descriptive)
4) Assessment of the temporal relationship between the severity of SARS-CoV-2 infection and death
5) Assessment of regional differences in management and clinical outcome (descriptive)
6) Monitoring different trends over time (symptoms, incidence) (descriptive)
7) Estimation of direct health care costs based on length of stay, time on ICU, time with mechanical ventilation, time on ECMO (descriptive)
8) Cost utilization based on coded DRG and reimbursement (descriptive)
9) Assessment of the relationship between SARS-CoV-2 and the health economic burden in terms of direct treatment costs incurred during hospitalization (descriptive)
10) To describe the clinical pattern of disease: Sequence and reversibility of symptoms (descriptive), sequence of radiographic imaging findings (descriptive), sequence of laboratory lab results and patterns of disease severity (descriptive, multivariable binary logistic regression model), sequence of virus detection and quantity in various bodily fluids and samples (descriptive), immunological / inflammatory features of severe infection (descriptive, multivariable binary logistic regression model)

end of 1:1-Block secondary endpoint
start of 1:n-Block recruitment countries

Countries of Recruitment

  •   Belgium
  •   Germany
  •   France
  •   Italy
  •   Ireland
  •   Portugal
  •   Spain
  •   Austria
  •   Iceland
  •   Switzerland
  •   United Kingdom
end of 1:n-Block recruitment countries
start of 1:n-Block recruitment locations

Locations of Recruitment

  • Medical Center 
  • Medical Center 
  • University Medical Center 
  • Medical Center 
  • University Medical Center 
  • Medical Center 
  • University Medical Center 
  • University Medical Center 
  • University Medical Center 
  • University Medical Center 
  • University Medical Center 
  • University Medical Center 
  • University Medical Center 
  • University Medical Center 
  • University Medical Center 
  • Medical Center 
  • Medical Center 
  • Medical Center 
  • Medical Center 
  • Medical Center 
  • University Medical Center 
  • Medical Center 
  • University Medical Center 
  • University Medical Center 
  • University Medical Center 
  • Medical Center 
  • University Medical Center 
  • Medical Center 
  • University Medical Center 
  • Medical Center 
  • University Medical Center 
  • Medical Center 
  • University Medical Center 
  • Medical Center 
  • Medical Center 
  • other 
  • Medical Center 
  • Doctor's Practice 
  • Medical Center 
  • other 
  • University Medical Center 
  • University Medical Center 
end of 1:n-Block recruitment locations
start of 1:1-Block recruitment

Recruitment

  •   Actual
  •   2020/03/16
  •   20000
  •   Multicenter trial
  •   International
end of 1:1-Block recruitment
start of 1:1-Block inclusion criteria

Inclusion Criteria

  •   Both, male and female
  •   no minimum age
  •   no maximum age
end of 1:1-Block inclusion criteria
start of 1:1-Block inclusion criteria add

Additional Inclusion Criteria

Patients with confirmed SARS-CoV-2 infection by PCR diagnosis from nasopharynx, oropharynx, stool, or blood. Rapid tests are an acceptable alternative.

end of 1:1-Block inclusion criteria add
start of 1:1-Block exclusion criteria

Exclusion Criteria

The study will be governed, announced, and disseminated via ESCMID and other channels across Europe. However, treatment in another country is not a formal exclusion criterion.

end of 1:1-Block exclusion criteria
start of 1:n-Block addresses

Addresses

  • start of 1:1-Block address primary-sponsor
    • Deutsches Zentrum für Infektionsforschung (DZIF) e. V.
    • Inhoffenstr. 7
    • 38124  Braunschweig
    • Germany
    end of 1:1-Block address primary-sponsor
    start of 1:1-Block address contact primary-sponsor
    end of 1:1-Block address contact primary-sponsor
  • start of 1:1-Block address scientific-contact
    • University Hospital of Cologne, Faculty of Medicine and University Hospital Cologne, Department I for Internal Medicine, Cologne, Germany
    • Mr.  Prof.  Jörg Janne  Vehreschild 
    • Herderstraße 52-54
    • 50931  Köln
    • Germany
    end of 1:1-Block address scientific-contact
    start of 1:1-Block address contact scientific-contact
    end of 1:1-Block address contact scientific-contact
  • start of 1:1-Block address public-contact
    • University Hospital of Cologne, Faculty of Medicine and University Hospital Cologne, Department I for Internal Medicine, Cologne, Germany
    • Mr.  Prof.  Jörg Janne  Vehreschild 
    • Herderstraße 52-54
    • 50931  Köln
    • Germany
    end of 1:1-Block address public-contact
    start of 1:1-Block address contact public-contact
    end of 1:1-Block address contact public-contact
end of 1:n-Block addresses
start of 1:n-Block material support

Sources of Monetary or Material Support

  • start of 1:1-Block address materialSupport
    • Deutsches Zentrum für Infektionsforschung (DZIF)
    • Inhoffenstr. 7
    • 38124  Braunschweig
    • Germany
    end of 1:1-Block address materialSupport
    start of 1:1-Block address contact materialSupport
    end of 1:1-Block address contact materialSupport
  • start of 1:1-Block address otherSupport
    • Willy Robert Pitzer Stiftung
    • Myliusstraße 30
    • 60323 F  Frankfurt am Main
    • Germany
    end of 1:1-Block address otherSupport
    start of 1:1-Block address contact otherSupport
    end of 1:1-Block address contact otherSupport
end of 1:n-Block material support
start of 1:1-Block state

Status

  •   Recruiting ongoing
  •   [---]*
end of 1:1-Block state
start of 1:n-Block publications

Trial Publications, Results and other Documents

end of 1:n-Block publications
* This entry means the parameter is not applicable or has not been set.